Andrew A. F. Hack has bought stock on 10 days since Nov 2020

Andrew A. F. Hack, M.D., Ph.D., is a corporate director and life sciences investor who serves on the board of Nuvalent, Inc. as a director.( A Partner and Managing Director at Bain Capital Life Sciences, he brings extensive experience in biotechnology and healthcare investing to Nuvalent’s board, where he has served since 2021.( In this role, Hack is involved in strategic oversight of Nuvalent’s efforts to develop precisely targeted kinase inhibitors for treatment‑resistant cancers.(

Hack’s career spans senior investment and operating roles across the biopharmaceutical sector, including serving as Chief Financial Officer of Editas Medicine, Inc. from 2015 to 2019 and portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology and pharmaceutical companies.( He has held healthcare analyst positions at HealthCor Management and other hedge funds, and earlier was Director of Life Sciences and co‑founder of Reify Corporation, a life science tools and drug discovery company.( Hack currently serves on multiple public company boards, including Dynavax Technologies, Mersana Therapeutics, Atea Pharmaceuticals, and BCLS Acquisition Corp.( He holds a B.A. in biology with special honors and both an M.D. and Ph.D. in molecular genetics and cell biology from the University of Chicago.(

Written by Perplexity from public sources.